Pneumonia treated with rifampicine attenuates inflammatio

Phase 4

Completed

• Conditions: pneumonia; respiratory tract infection; 10004018; 10024970

• Registration Number: NL-OMON39089
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1. Patient aged 18 years or above
2. Community acquired pneumonia with CURB65 score >= 2;OR
1. Patient aged 18 years or above
• hospitalized for community acquired pneumonia, and
• clinical suspicion of pneumococcal pneumonia because of one or more of these features:
o pleuritic chest pain, or
o acute onset of symptoms, or
o cardiovascular disease in medical history, or
o leukocyte count > 15 x10e9/l (4), or
o on chest X-ray: an alveolar pattern (lobar, segmental or sub-segmental infiltrate) (5)

Exclusion Criteria

• Known allergy to rifampicin or anaemia or thrombopenia as side effect of rifampicin in medical history ;• Medication induced hepatitis or acute liver failure;• Porphyria;• Use of voriconazol or protease inhibitors ;• Female patients who are pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified